At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
IVW-1001 Ophthalmic Eyelid Wipe 0.1% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1/2a, Proof-of-Concept, Multicenter, Parallel, Vehicle-Controlled, Double-Masked, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of IVW-1001 Ophthalmic Eyelid Wipe in Subjects With Dry Eye Disease
In Brief
A Phase 2 clinical trial evaluating IVW-1001 Ophthalmic Eyelid Wipe 0.1%, IVW-1001 Ophthalmic Eyelid Wipe 0.2%, and 1 other intervention for Dry Eye Disease. Completed, enrolled 150 participants across 1 site.
Detailed Summary
Double-masked, dose-response, trial of IVW-1001 in subjects with dry eye disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20252026
First PostedMay 2024
Enrollment StartJun 2024
Primary CompletionOct 2024
TodayJul 2026
First PostedMay 6, 2024
Enrollment StartJun 25, 2024
Primary CompletionOct 15, 2024
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 2.2 years ago
Interventions
IVW-1001 Ophthalmic Eyelid Wipe 0.1%drug
IVW-1001 Ophthalmic Eyelid Wipe 0.1%
IVW-1001 Ophthalmic Eyelid Wipe 0.2%drug
IVW-1001 Ophthalmic Eyelid Wipe 0.2%
IVW-1001 Placebodrug
IVW-1001 Placebo